Amneal Pharmaceuticals, Inc. AMRX Specialty — Operating loss

Similar metrics at other companies

APGSpecialty Services — Operating Income (Loss)

$39M+34.5%

BCPCSpecialty Products — Operating Income (Loss)

$11.94M+24.5%

MLMSpecialties — Operating Income

$35M+6.1%

GTLSSpecialty Products — Operating Income (Loss)

$8.4M-82.6%

HSICGlobal Specialty Products — Operating Income

$58M+3.6%

THGSpecialty Lines — Operating Income

$84M+30.0%

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s specialty — operating loss?

Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — operating loss of $29M in Q4 2025.

How has Amneal Pharmaceuticals, Inc.'s specialty — operating loss changed year-over-year?

Amneal Pharmaceuticals, Inc.'s specialty — operating loss increased by 2.1% year-over-year, from $28.4M to $29M.

What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — operating loss?

Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — operating loss has grown at a 19.7% compound annual growth rate (CAGR), from $56.42M to $116M.

What does specialty — operating loss mean?

Indicates the extent to which a business segment's operating expenses exceed its gross revenue. A persistent operating loss suggests that the segment is not yet self-sustaining or is facing significant competitive or cost pressures.